Another coronavirus vaccine candidate enters the fray

5 June 2020

A COVID-19 vaccine candidate hatched at the University of Queensland (UQ) is at the heart of a new collaboration with CSL Ltd (ASX: CSL) and CEPI, the Coalition for Epidemic Preparedness Innovations.

The project will seek to accelerate the development, manufacture and distribution of the candidate, formalizing support provided by CSL to UQ and CEPI from the outset of the pandemic earlier this year.

CSL is already working with US antibody specialist SAB Biotherapeutics (SAB) to rapidly develop SAB-185, a COVID-19 therapeutic candidate said to be on track for testing in the coming months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK